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ABSTRACT: Capillary zone electrophoresis-mass spectrometry (CE-MS) is a
mature analytical tool for the efficient profiling of (highly) polar and ionizable
compounds. However, the use of CE-MS in comparison to other separation
techniques remains underrepresented in metabolomics, as this analytical approach
is still perceived as technically challenging and less reproducible, notably for
migration time. The latter is key for a reliable comparison of metabolic profiles and
for unknown biomarker identification that is complementary to high resolution
MS/MS. In this work, we present the results of a Metabo-ring trial involving 16
CE-MS platforms among 13 different laboratories spanning two continents. The
goal was to assess the reproducibility and identification capability of CE-MS by
employing effective electrophoretic mobility (μeff) as the key parameter in
comparison to the relative migration time (RMT) approach. For this purpose, a
representative cationic metabolite mixture in water, pretreated human plasma, and
urine samples spiked with the same metabolite mixture were used and distributed for analysis by all laboratories. The μeff was
determined for all metabolites spiked into each sample. The background electrolyte (BGE) was prepared and employed by each
participating lab following the same protocol. All other parameters (capillary, interface, injection volume, voltage ramp, temperature,
capillary conditioning, and rinsing procedure, etc.) were left to the discretion of the contributing laboratories. The results revealed
that the reproducibility of the μeff for 20 out of the 21 model compounds was below 3.1% vs 10.9% for RMT, regardless of the huge
heterogeneity in experimental conditions and platforms across the 13 laboratories. Overall, this Metabo-ring trial demonstrated that
CE-MS is a viable and reproducible approach for metabolomics.
The state-of-the-art MS instrumentation used in metab-olomics typically provides a read-out of thousands of
molecular features in a given biological sample within a single
run when rigorous data filtering is not applied to reject a large
fraction of spurious signals, redundant ions, and background
contaminants.1 The annotation of these features to specific
compounds is currently one of the key challenges in
metabolomics and is often performed using library-based
approaches, corresponding to annotation at various confidence
levels according to international guidelines (e.g., Metabolomics
Society).2−5 Ideally, only parameters presenting good reprodu-
cibility and low bias, such as exact mass, should be used and
crossed to reach high identification confidence.3,6 However,
other important parameters, such as retention time in LC, may
lack consistency from one laboratory to another due to the
difficulty to standardize all the operating parameters. This is
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particularly the case for the analysis of polar compounds using
HILIC conditions where the chemistry and the age of the
column, as well as the injection solvent and sample matrix
including the preparation of themobile phase, may yield variable
conditions in separation. To tackle this challenge, several
laboratories have resorted to experimentally building metab-
olomic libraries for compound identification purposes in house,
an often time-consuming and relatively expensive effort.
Capillary zone electrophoresis (CE) coupled to mass
spectrometry (MS) is highly suited for the profiling of polar
and charged metabolites, notably for compound classes such as
nucleotides, sugar phosphates, organic acids, nucleosides, and
amino acids.7−13 In metabolomics, the use of CE-MS is
considerably underrepresented in comparison to other analytical
techniques.14,15 Over the past few years, various research groups
have shown the utility of CE-MS for biomarker discovery studies
using both large and small sample sets. For example, Harada et
al. assessed the long-term performance of CE-MS for metabolic
profiling of more than 8000 human plasma samples from the
Tsuruoka Metabolomics Cohort Study over a 52-month
period.16 Mischak and co-workers have profiled native peptides
in more than 20,000 human urine samples by CE-MS with an
acceptable interlaboratory reproducibility.17−20 Onjiko et al.
used CE-MS to phenotype cell types in single cells of developing
frog embryos.21 Very recently, CE-MS has shown good mutual
agreement (mean bias < 15%) for reliable quantification of
various plasma/serum metabolites and fatty acids as compared
to reversed-phase LC-MS and GC-MS.22,23 Overall, all these
studies demonstrate the usefulness and added value of CE-MS in
the field of metabolomics. However, the separation science
community still perceives this analytical technique as technically
challenging and less reproducible, especially in terms of
migration time among comparative metabolic profiling studies
using gas and liquid chromatography.24−26
Migration-time reproducibility is of utmost importance for
reliable metabolomics. It aids comparison of metabolic profiles,
including scrutinizing samples for subtle changes in profiles/
patterns in comparative metabolomics studies, and facilitates the
identification of unknown metabolites. In CE-MS analysis,
variability in migration time arises from fluctuations in the
electro-osmotic flow (EOF), temperature, physicochemical
properties of solvents and the capillary, often due to frequently
matrix-induced capillary surface interactions, among other
factors. In contrast to chromatographic-based separation
techniques, (open-access or commercial) software tools for
effectively correcting shifts in migration times are still lacking,
despite a high need to improve overall data robustness for
enhancing analytical robustness. Nemes et al. employed
nonlinear time warping to reduce relative errors from ∼5−
10% to ∼0.3% for migration times, thus substantially aiding
metabolite identifications.27 More recently, Gonzaĺez-Ruiz et al.
tackled this challenge by developing a software, called
ROMANCE, which converts the migration time scale into an
effective electrophoretic mobility (μeff) scale.
28 The approach
demonstrated effective correction of EOF-caused shifts in
migration times, albeit in a small cohort of samples, thus being
able to improve the reproducibility of the migration index below
1.5%. The use of μeff raises the potential to aid compound
identification in biological samples, notably when using
metabolite libraries of electrophoretic mobilities. Such chemical
libraries prove especially useful in CE, where migration times
may exhibit higher variability.
In 2018, Drouin et al. published the first μeff database for 458
endogenous metabolites,29 as well as its use to identify
compounds across different laboratories. However, the utility
of this approach was examined only by a single individual
responsible for preparing the BGE and analyzing the samples in
two different laboratories. On the basis of this study, we present
the results of the Metabo-ring study in which μeff on migration-
time reproducibility and identification capability in CE-MS-
based metabolomics was assessed. The study encompassed 13
independent laboratories from academia and companies
spanning 11 countries of 2 continents. All participants used
the same batch of samples, consisting of a representative
metabolite mixture, human plasma and urine (both matrices
used at zero-, five- and 10-fold diluted form) spiked with the
same representative metabolite mixture. Each participating lab
prepared and employed the same background electrolyte (BGE)
on the basis of a protocol. All other parameters (capillary,
interface, injection volume, voltage ramp, temperature, type of
instrument used, and capillary conditioning and rinsing
procedures, etc.) were left to the discretion of the participating
laboratories. The key parameters assessed by this Metabo-ring
were the reproducibility of relative migration time (RMT) and
the μeff across the laboratories, which was determined for a
representative set of cationic metabolites in each sample.
■ EXPERIMENTAL SECTION
Chemicals. Acetonitrile (MeCN) and dichloromethane
were purchased from Actu-All Chemicals (Oss, The Nether-
lands) and Biosolves (Valkenswaard, The Netherlands),
respectively. Spermine, thiamine, choline, tryptamine, creatine,
L-neopterin, trans-4-hydroxy-L-proline, and inosine were
obtained from Sigma-Aldrich (Steinheim, Germany). L-arginine,
L-isoleucine, L-leucine, L-tryptophan, L-proline, L-glutamine, L-
lysine, histamine, adenosine and procaine were supplied from
Fluka (Buchs, Switzerland). Agmatine, adenine, and serotonin
were purchased from Alfa Aesar (Kandel, Germany). Para-
cetamol and nicotine were obtained from Dr. Ehrenstorfer
(Augsburg, Germany) and Carl Roth (Karlsruhe, Germany),
respectively. MS-grade water was provided through a Milli-Q
Advantage A10 water purification system (Merck, Darmstadt,
Germany).
Study Design. The goal of this study was to assess the
migration-time reproducibility of CE-MS for metabolomics and
determine the most suitable approach for metabolite annotation
by comparing RMT versus μeff in standardized condition of
BGE. Changes in BGE composition (and thus pH and ionic
strength) are one of the main sources of variability in separation
in CE across laboratories. BGE in CE-MS-based metabolomics
studies often use volatile buffers such as ammonium acetate/
formate, acetic acid, and formic acid.30−32 Over the past few
years, the use of 10% acetic acid gained interest for the efficient
profiling of cationic metabolites by CE-MS.33−35 This BGE is
relatively easy to prepare and does not require pH adjustment.
Moreover, in comparison to formic acid based BGE, it generates
low CE currents, making it more suitable for the sheathless
interface and also interesting for anionic metabolic profiling due
to its slightly higher pH.36,37 Though it is not a strict buffer
solution, this BGE can be used the whole day for analyses.
Although the replenishment of the BGE is recommended before
each analysis batch,38 it has been shown that 10% acetic acid can
be conserved over an extended period, giving consistent μeff.
28
Therefore, the present work adopted 10% acetic acid (pH∼ 2.2)
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as the BGE, which was prepared independently in each
participating laboratory.
For maximal impact, this interlaboratory study involved 20
different CE-MS platforms across 17 different laboratories. Each
laboratory was provided with a set of 7 samples, including one
cationic mix of 23 compounds in water (21 cationic metabolites
and 2 internal standards, Table S1) and six samples prepared by
mixing the standard solution with different levels of matrices
extracted from human plasma and urine subjected to null, 5- and
10-fold dilution, separately. All the samples included para-
cetamol and procaine as markers for EOF time. To facilitate
adoptability, our goal was to minimize or avoid modifications to
routine practices of each lab by providing a freedom in
experimental conditions and CE-MS instruments used, thereby
making this study design unique in comparison to previous ring
trials.39−41
Because μeff is only dependent on the BGE composition, its
preparation and the hydrodynamic injection mode without
stacking were imposed to every participant. Stacking in CE is
performed by changing the sample and/or separation conditions
to induce a change in analyte velocity. In this study, all
participants have been requested to use CE-MS separation
conditions without implementing a stacking procedure,
including the use of electrokinetic injection (the latter being
selective to high-mobility compounds). Other parameters, such
as capillary length, capillary diameter, voltage, pressure, or ESI
source parameters, were left to the discretion of each group. For
minimal statistical treatment, every sample was analyzed in
technical triplicates, and the injection order was at the discretion
of the participants. The nature of each sample (i.e., matrix
composition and a neutral marker for EOF time) was
communicated to the different groups to guide procedures in
capillary rinsing between runs and total acquisition time.
Samples. Stock solutions of the analyte standards were
prepared in water at a concentration of 1 mg/mL. Paracetamol
was included at 3 mg/mL to aid signal detection for marking the
EOF time. The stock solutions were stored at −20 °C until
usage. The standards were prepared by diluting the stock
solutions in water to 20 μg/mL for every compound, except
paracetamol (30 μg/mL). Pooled human plasma was obtained
from Sanquin (Amsterdam, The Netherlands). In 2 mL
Eppendorf tubes with 500 μL plasma, 1000 μL of MeCN was
added for protein precipitation, assisted by shaking for 5 min at
12000g on an orbital shaking table. After centrifugation at
12000g for 5 min at 4 °C, 1800 μL of supernatant was later
collected from each tube and combined together. The combined
supernatant was then split into aliquots of 1800 μL, which were
evaporated to dryness using a SpeedVac and reconstituted with
600 μL of the standard solution. Dichloromethane (400 μL) was
mixed with 500 μL of the reconstituted samples. After agitation
for 5 min, 450 μL of the aqueous phase was collected and filtered
through centrifugal ultrafilters with a 3 kDa cutoff membrane
from Millipore (Milford, MA, USA) at 12,000g for 2 h at 4 °C.
The filtrates from different tubes were combined together. The
resulting contaminant’s concentrations (excluding lipids and
proteins) of this solution were supposed to be identical to the
raw plasma. Five- and ten-time dilutions of this filtrate were
prepared via dilution using the water-based standard solution.
Finally, the three samples containing different levels of extracted
plasma matrix were split into 100 μL aliquots and stored at −80
°C until shipment over dry ice.
The pooled urine samples were obtained from a group of
healthy volunteers. In order to produce a sufficient number of
samples, multiple aliquots were prepared in parallel. Briefly,
1000 μL of pooled urine was evaporated to dryness with a
SpeedVac and then reconstituted with the standard solution in
water. The reconstituted samples were ultrafiltrated through a 3
kDa cutoffmembrane at 12,000g for 2 h at 4 °C, followed by the
merging of all the filtered solutions. The resulting solution
contains the same contaminant content as raw urine. Five- and
ten-time dilutions were prepared similarly as plasma-based
samples via dilution in the standard solution. Finally, the three
urine-based samples were split into 100 μL aliquots and stored at
−80 °C until shipment in dry ice.
BGE Preparation. Every participating laboratory used 10%
acetic acid as the BGE, prepared following the same protocol to
aid reproducibility. Briefly, approximately 80 mL of MS grade
water was first added in a 100 mL volumetric flask, followed by
the addition of 10.00 mL acetic acid (MS grade). The BGE
preparation was completed by further adding water until the
gauge line.
Instrumentation. Seventeen laboratories, with 20 different
CE-MS platforms in total, were involved in this interlaboratory
study, of which 11 systems employed a sheath−liquid (SL)
interface and 9 employed a sheathless interface for coupling CE
to MS. Among them, 10 platforms used a sheath−liquid
interface based on a coaxial tube interface from Agilent
Technologies. Except for one platform using CESI 8000 plus
capillary electrophoresis system with a sheathless CE−ESI
interface, all the other platforms with a coaxial sheath-flow ESI
interface used a custom-built CE-ESI platform or the Agilent
7100 capillary electrophoresis system (Agilent Technologies,
Waldbronn, Germany). The SL interface was compatible with a
large variety of operational conditions, therefore a variety of
protocols were used during this study. Fused silica capillary with
internal diameters of 40 or 50 μm and different lengths (from 60
to 105 cm)were used with the sheath−liquid interface across the
laboratories. During this study, each lab used their own
(preferred) sheath−liquid composition and flow-rate. The
sheath−liquid-based CE systems were coupled to various
types of mass spectrometers from different manufacturers,
namely, the 6510, 6540, 6550, 6560 QTOF, 6230 TOF, and
6490 QqQ from Agilent (Santa Clara, CA) as well as the Impact
HD andmaXis-3GQTOFMS fromBruker (Bremen, Germany).
The other CE-MS system consisted of a homemade CE system
and a custom-built low-flow sheath−liquid interface coupled to
a Bruker Impact HD QTOF (Bremen, Germany). On this
platform a fused silica capillary of 40 μm internal diameter and
105 cm length was used,42,43 and the flow-rate of the sheath−
liquid was 0.6 μL/min, whereas in commercial sheath−liquid
interfaces, the sheath−liquid is typically provided at a flow rate
in the range from 3 to 10 μL/min.
The remaining 9 platforms made use of a sheathless interface
with a porous tip, which was coupled to MS via a Nanospray
source. This interface obtained from AB Sciex (Brea, CA),
employed a silica capillary with a 30 μm internal diameter and a
91 cm length and required a CESI 8000 plus capillary
electrophoresis system also provided by AB Sciex. The CESI
interface is compatible with a large variety of nanoESI sources.
Consequently, in addition to AB Sciex mass spectrometers
(TripleTOF 6600, 5600, QTrap 6500, 6500 plus QQQ), the
CESI interface has been used during this study on some other
MS brands, such as Bruker (MicrOTOF-Q II and Impact
quadrupole time-of-flight) and Thermo Fisher (Q-Exactive
HF). Whereas the sheath−liquid interfaces were used with short
ramp up of voltage (from 1 to 0.5 min), due to its original design,
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the sheathless interface required longer voltage ramps for the
sake of current stability (from 1 to 2 min). Apart from the large
variety of instrumentation used, each laboratory used their own
capillary conditioning and washing procedure. Both capillary
and room temperatures used during analyses by different
laboratories ranged from 20 to 25 °C. More details about the
experimental conditions used with each platform are given in
Table S2.
Data Processing. Initially, 17 groups were involved in this
Metabo-ring trial. One data set was triaged as peak widths about
5 min at baseline were obtained which is unusual for capillary
electrophoretic separations of small molecules. Therefore, this
data set was excluded from further data processing. The primary
MS data were received and centralized as manufacturer raw data
and processed using Skyline.44 The data files from Bruker
instruments were converted into mzML format using
MSConvert45 prior to their import into Skyline.
For robust and transposable results from one laboratory to
another, a two-marker conversion was used for μeff determi-
nation using an in-house software. Paracetamol (μeff = 0 mm
2
kV−1 min−2) and procaine (μeff = 1559 mm
2 kV−1 min−1) were
used as references for μeff calculation.
36,46 For accurate μeff
measurements, the migration time has to be considered from the
start of voltage application. Therefore, when necessary, the
migration time was corrected to synchronize the MS acquisition
with the voltage start. For the same purpose, the voltage ramps
have also been considered during the conversion intomobility.46
RMTs were calculated using procaine as a reference compound.
Bias represents the deviation of a measured value (Xm) (here
RMT or μeff) to a reference (Xr). For this purpose, the average
μeff and RMT (Table S1) values measured from standard









When possible, leucine and isoleucine were processed as two
distinct peaks, otherwise the same values were attributed to both
compounds.
■ RESULTS AND DISCUSSIONS
Relevance of Standardization of BGE Preparation. The
present work adopted 10% acetic acid (pH ∼ 2.2) as the BGE,
which was prepared independently in each participating
laboratory. Figure 1 shows an electropherogram obtained for
the analysis of a standard mixture of cationic metabolites by
sheath−liquid CE-MS using 10% acetic acid as BGE, clearly
indicating that a high separation efficiency is provided by the use
of this BGE.
Repeatability and reproducibility were quantified based on
the data collected from 19 CE-MS platforms (Figure 2). The
intralaboratory repeatability of the measurements of both μeff
and RMT was typically below 1% for the test compounds in
water for three consecutive analyses. The average reproducibility
of these parameters was about 4.3% and 5.7%, respectively, with
a maximum observed for inosine in both cases. Therefore, these
findings clearly indicate the presence of a significant
contribution of the interlaboratory variability, leading to higher
values of relative standard deviation (RSD) for reproducibility.
To find the main source for the observed variation, we
determined the bias of each compound as measured by each
individual analytical platform. Figure 2 reveals a relatively high
degree of variation, especially for the slower-migrating
compounds (longer migration times). This is expected since
for a constant measurement uncertainty, the relative error
increases as the reference values get closer to 0, as it is the case in
the μeff scale (Table S1).
Interestingly, three data sets presented a lower μeff for the late-
migrating compounds (i.e., L-isoleucine, L-leucine, L-tryptophan,
L-glutamine, L-proline, L-neopterin, trans-4-hydroxyproline, and
inosine) as compared to the data obtained by the other 16 CE-
MS platforms (Figure 2). Since μeff is theoretically influenced by
the physicochemical properties of the BGE only, this
phenomenon was explained by variation in BGE preparation.
Indeed, slow-migrating cationic compounds usually present a
low electrical charge due to their basic functions with low pKa or
due to presence of an acidic function with high pKa.
Consequently, their μeff is greatly influenced by any slight
variation of the acidity of the BGE. Therefore, with a pKa of 2.74,
inosine was the slowest compound and also the compound with
Figure 1. Typical profile obtained for the analysis of a standard mixture
of cationic metabolites by CE-MS (platform 19, see Table S2) using
10% acetic acid as BGE.
Figure 2. Individual bias to the average and interlaboratory
reproducibility of μeff as obtained for the analysis of cationic metabolite
standards by 19 CE-MS platforms. Green and red lines mark bias
thresholds at ±5 and ±10%, respectively. Metabolites are presented in
decreasing mobility order from left to right.
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a relatively high μeff variability. Consequently, results from these
3 platforms were triaged from further data analysis in the rest of
the study (Table S2).
Effective Electrophoretic Mobility vs Relative Migra-
tion Time. It is relatively feasible to mitigate variations in
migration time resulting from the BGE with added control over
buffer composition. While it is possible to control suction effect
from the ionization source, it may be difficult to tackle the
adsorption of matrix components onto the inner capillary
wall.28,47,48 To correct for these sources of variability, the most
popular method is the use of RMT.40,49,50 This approach
consists of comparing the velocity of the analyte (vanalyte) to that
of an internal standard (IS) (vIS). Both velocities are explained
by the electrophoretic movement of BGE and their electro-
phoretic movement (μEOF and μeff, respectively) under an
electric field (E) as well as the hydrodynamic movement of the
BGE (vhydrodynamic), such siphoning between the position of the
inlet and the outlet of the CE capillary tip, the sheath flow
surrounding of the CE capillary in the ESI source, the close-by
vacuum of the atmospheric interface of the mass spectrometer,
and pressure that may be applied during the separation. As
expressed in eq 2, the hydrodynamic phenomena exert an
additive effect instead of a proportional one and, therefore, they
cannot be accurately corrected by a ratio approach, making the




















A correction based on RMT can be powerful for compounds
migrating in proximity to the IS as they are subject to the same
variation of the hydrodynamic phenomenon. However, this
approach has limited ability to correct the migration of
compounds far from the IS.28 On the other hand, μeff depends
on the hydrodynamic radius (r), the ionic charge of the







Therefore, μeff is independent of BGE velocity and is only
influenced by its physicochemical properties. This parameter is
measurable using a neutral marker combined with the
experimental conditions. In this study, we have chosen for a
conversion based on two markers (c.a. procaine and para-
cetamol) in order to obtain μeff values which are independent of
the operational conditions across the laboratories, such as
capillary length, electric field, and temperature.46,51
Indeed, our measurements confirmed the viability of using μeff
as depicted in Figure 3; the μeff presented a bias below 3.1% for
all compounds except for inosine, while for the same set of
metabolites, RMT showed bias up to 11%. For compounds such
as tryptophan, μeff presented a variation up to 5-times lower than
the corresponding RMT. Interestingly, while the reproducibility
of μeff remained stable in a range from 0.8 to 3.1% for
compounds with high and medium μeff, RMTs trended with
migration time. Indeed, as shown in Figure 3B, minimal
dispersion of the RMT values was observed for the compounds
with migration time similar to that of the IS, whereas metabolites
with extreme RMT presented with a high interlaboratory
variability.
As the approach using the in-house metabolite library is based
on the relative error to a reference value (i.e., the average μeff), it
is important to observe the bias of each parameter. As shown in
Figure 3A, excluding inosine, 98% of the μeff measurements are
within a 5% bias limit, while 6 platforms presented RMT outside
those limits (Figure 3B), with themaximal bias up to 28%. These
results confirm the theoretical normalization power of the μeff
conversion of MT in comparison to RMT, especially in the
context of creating an interlaboratory database.
Influence of Sample Composition. High chemical
complexity in plasma and urine are known to challenge
molecular identifications and quantification due to matrix
effects as well as instrument performance and longevity. In
CZE, it is well-known that the ionic strength in the sample zone
influences the migration speed of the compounds at the start of
the separation. Therefore, high salt concentrations in such
complex biological samples can lead to lower signal-to-noise
ratios due to peak broadening and distortions in peak shapes and
shifts in migration indices (migration time, RMT, and μeff).
Figure 3. Individual bias and interlaboratory variability of μeff (A) and RMT (B) as determined for the analysis of standard metabolite mixture by 16
CE-MS platforms. The green and red lines denote a 5% and 10% threshold, respectively. Metabolites are presented in decreasing mobility order from
left to right.
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While a “dilute and shoot” approach is viable for urine,
deproteinization is usually necessary for plasma performed
before analysis as preventive measures. Deproteinization is
mostly performed in organic solvents (e.g., methanol or
acetonitrile), followed by rigorous vortex shaking and an
evaporation-to-dryness of the supernatant after which the
dried extract is reconstituted into an appropriate solvent and
volume for the follow-up instrumental analysis.52 However,
these purification steps do not adequately address high salt
content in urine and plasma.
To evaluate the influence of sample conductivity, samples
with different dilutions of urine and plasma matrices were
Figure 4. Individual bias and interlaboratory variability of μeff for cationic metabolites in complex biological matrixes: plasma (A, C, and E) and urine
(B, D, and F) at three different concentrations (undiluted: A and B; 5-times dilution: C and D; 10-times dilution: E and F) by 16 CE-MS platforms.
Metabolites are presented in decreasing mobility order from left to right.
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analyzed. These concentrations represented an equivalent of
undiluted, 5- and 10-times dilution of the biological fluids. As
shown in Figure 4, the μeff reproducibility remained globally
unaffected irrespective of the type and concentration of the
biological matrix. However, some trends of bias can be observed
when platforms are considered individually for each metabolite.
Fast-migrating compounds (e.g., spermine, histamine, agmatine,
and nicotine) presented a bias up to 18% in both undiluted
plasma and urine samples (Figure 4A,B). As highlighted in
Figure 4C,E and D,F for μeff and RMT, respectively, these
deviations to the baseline decrease with concentration of the
matrix (see the dilution factor).
We explain these variations by deformations of the peak for
the 4 fastest-migrating metabolites. With migration in a close
proximity to the sodium peak, these compounds experience peak
broadening. In some extreme cases, the ion suppression induced
by sodium can suppress a part of the peak leading to an incorrect
detection of its apex (see Figure S1). As shown in Figure 4C,E,
with the exception of inosine, 15 platforms presented a bias
below 5% and one with a bias below 7% in 5-times diluted
plasma. Further dilution of the samples (10-times) led to bias
below 5% for all platform and compounds, except for inosine
due to slight variation in BGE composition as discussed above.
Concerning urine, results were highly similar to only one CE
platform presenting a bias above 5% from samples diluted 5-fold,
excluding inosine. However, as shown in Figure 4F, one platform
presented higher deviation for spermine compared to more
concentrated samples (Figure D). No explanation has been
found so far to explain this deviation in the 10-fold diluted
samples while no drift was observed in the 5-fold dilution of
urine.
Proposed: Metabolite Identification Guidelines Based
on a Common Library. This work demonstrated the utility of
an interlaboratory CE-MS database to enhance metabolomics.
With the use of standardized BGE conditions (10% acetic acid
here), conversion from migration times to μeff was found to
efficiently normalize separation between 13 different laborato-
ries with interlaboratory variability below 3.1% for 20 of the 21
compounds considered.
For sake of comparison with gold standard in feature
annotation in metabolomics, collisional cross section are
among the most reproducible parameters with interlaboratory
variation in the range of 2%36,41,53 and 5% and are usually the
threshold for identification confirmation.6,54 Although HILIC is
a powerful method to separate polar compounds, deviation of
the retention time up to 10% to in-house databases are usually
considered for feature annotation.6
As a first approach, we propose that such a scoring system can
be based on different ranges of bias between μeff measurements
and μeff values in databases (Table 1). Such databases should be
built on a reliable manner, taking into consideration multiple
technical replicates, performed in multiple laboratories, and
involving different instruments. Using 10% acetic acid as the
BGE, the deviation to the consensus value below 10% was easily
achieved for most metabolites in complex biological matrices. By
using a system suitability test based on a short panel of
compounds with different migration speeds, we envision it
possible to test the BGE and assess whether it is performing
conformed to the database. For example, our data here
exemplified μeff measurements with a bias below 5%, thus
provided an added piece of information to credential
compounds and aid identifications (Table 1). Further,
credentialing may consider electrophoretic migration for
added fidelity.
As the mobility of slow-migrating compounds is more
dependent on the differences of physicochemical properties of
the BGE, conversion to μeff overestimates relative bias and
reproducibility. For instance, in the case of inosine, μeff
presented a considerably low absolute deviation on all platforms
with a maximum deviation about ±10 mm2 kV−1 min−1 (Table
S1). Therefore, the use of absolute thresholds in μeff
29 may
enhance identification confidence for slow-migrating metabo-
lites. In the presence of standardized experimental conditions,
the normalization to and absolute use of μeff appears to provide
an added piece of compound-dependent information to aid the
identification of metabolites.
Next to the μeff, this study also highlights the annotation
capability of RMT, comparable to retention time in HILIC.6
Although the use of RMT shows interlaboratory variability and
bias below 10% for a very large majority of the compounds and
platforms, it has to be used cautiously since few platforms
presented very large deviations (up to 30%).
■ CONCLUSIONS
This study encompassing 13 laboratories and 16 platforms
spanning 11 countries and 2 continents found CE-MS a robust
and reproducible technology for metabolomics. Despite major
variations in experimental conditions, CE instruments and
methods, CE-ESI ion sources, and even users, conversion of
migration times into μeff reduced variability from 10.9% on RMT
to 3.1% in the μeff scale using the same BGE composition.
Tabulating μeff under specific BGE compositions into universal
database adds another compound-dependent and reliable value,
thus complementing traditional MS-MS/MS databases in
metabolomics (e.g., HMDB55 and Metlin56). The use of μeff
requires only a limited number of internal standards (e.g., two
different compounds used here) while substantially enhancing
compound identification in metabolomics via a targeted or
untargeted approach. On the basis of these results, we propose
here guidelines by using a scoring approach based on different
μeff criteria to support feature annotation in metabolomics.
Although this study focused on cationic small molecules only,
we anticipate that this approach also is easily extendable to
anionic metabolites, including but not limited to small organic
acids, nucleotides, and sugar phosphates.29 As LC-based
separations are often challenged for such compounds, we
anticipate this Metabo-ring trial to invigorate the use of CE-MS
with the μeff-based approach in metabolomics and other fields.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.analchem.0c03129.
(Table S1) Physicochemical properties of the metabolites
of interest (*: from ChemAxon, chemicalize.com,
consulted the 16th of July 2020) and (Figure S1)
Table 1. Proposition of Confidence Levels for Annotation of
Features Using μeff by CE-MS
confidence level
>100
mm2 kV−1 min−1 <100 mm2 kV−1 min−1
high <5% <10% or ±10
medium 5% < x < 10% 10% < x < 20% or ±20
low (rejected hypothesis) >10% >20% or > ±20
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extracted ion electropherograms of spermine (m/z
203.2230) in nondiluted plasma samples obtained by
CE-MS across 5 different laboratories (PDF)
(Table S2) Detailed CE-MS parameters (XLSX)
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d’Orleáns, 45067 Orleáns, France
Rouba Nasreddine − Institut de Chimie Organique et Analytique
(ICOA), CNRS FR 2708 - UMR 7311, Universite ́ d’Orleáns,
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